Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
laser777,
There are those who know that the markets are rigged, know they can’t do anything on their own to change it and have adjusted their investment strategy knowing that this is what is happening. There are opportunities to play along with their trades or set up speed bumps near tops or bottoms when a cycle is in play. The unsuspecting and naive can get caught in the traps being set because they are assuming that regulatory agencies are willing and able to protect them from this ongoing manipulation which they claim is just part of necessary market dynamics irregardless of defined illegality of some moves made within their actions. Such is the state of the market… for now. NWBO and others are working to change this. Best wishes.
dstock - I think you're on to something. It's as if a toddler was asked to match up a pile of index cards with the names of treatments written on them. No logic, just random picks. It's no different than the annual omnibus budget show, which no one reads, or knows what's in them. A couple of preselected congressional mouth pieces will whine about how quickly it passed, and how the exorbitant page count made it impossible to examine in so short a time. Then presto, no one remembers anything related to the subject the next day. You know what the omnibus bill really is? It's legalized congressional money laundering. Had that illicit enterprise not be forced to come to a screeching halt in 2019, perhaps there would have been some legit funds actually going to where they were actually designated to go. Now they're bottom fishing for anything they can scrape together.
I am indeed me, I stand by the comments I made.
As to what you and others believe, that is not my concern. Nor is it for me to convince you otherwise.
This is just a forum, nothing more, nothing less.
The commentary within has zero impact on any outcome of significance.
Why everyone does not have him on ignore is a tell. Some find it a personal ego attack and also believe the false illusion that they MUST respond to his bs, thus their insatiable need to respond. But its all a game the Ex's of these board have mastered, and the responders are the losers in this game. And they lose with every response, but cannot see that. Ignorance, in this case, is bliss.
Agreed Hope4patients that the spoofing damages inflicted on NWBO
and us shareholders may be in the 100s million dollars but additionally,
the damage inflicted by the MMs in delaying for years a treatment that
could have extended or even saved many patients lives is incalculable in
monetary terms and unfortunately that damage will not and cannot be used
to hold those criminals accountable for their despicable activities.
I can give credit to what you said. But first you have to confirm that you are the one who said the following.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174095255
biosectinvestor,
I went through all the trials on cancer SWOG was running. It seems like that SWOG is playing with various combinations of the different drugs from all the BPs. I haven't seen any extraordinary results from any of these trials. I am really curious about the objectives of these trials. Is SWOG trying to find some combinations that are really working? It seems like SWOG is trying to convince people that none of these combinations are working.
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
https://classic.clinicaltrials.gov/ct2/show/NCT04071457?recrs=ab&lead=swog&draw=2&rank=26
Daratumumab -- Janssen Biotech, Inc.
Lenalidomide -- Bristol Myers Squibb
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
https://classic.clinicaltrials.gov/ct2/show/NCT04205968?recrs=ab&lead=swog&draw=2&rank=24
Paclitaxel -- Bristol-Myers Squibb
Ramucirumab -- Eli Lilly
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)
https://classic.clinicaltrials.gov/ct2/show/NCT04510597?recrs=ab&lead=swog&draw=2&rank=21
Nivolumab -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Avelumab -- Merck KGaA and Pfizer
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04511013?recrs=ab&lead=swog&draw=2&rank=20
Binimetinib -- Pfizer
Encorafenib -- Pfizer
Ipilimumab -- Bristol-Myers Squibb
Nivolumab -- Bristol-Myers Squibb
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04625647?recrs=ab&lead=swog&draw=2&rank=19
Sotorasib -- Amgen
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04647916?recrs=ab&lead=swog&draw=2&rank=18
Sacituzumab Govitecan -- Gilead
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT05040360?recrs=ab&lead=swog&draw=2&rank=15
Capecitabine -- Roche
Temozolomide -- Merck
Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05364645?recrs=ab&lead=swog&draw=2&rank=14
Pemetrexed -- Eli Lilly
Selpercatinib -- Eli Lilly
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05561387?recrs=ab&lead=swog&draw=2&rank=12
Bortezomib -- Takeda
Daratumumab and Hyaluronidase-fihj -- Johnson & Johnson
Lenalidomide -- Bristol-Myers Squibb
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
https://classic.clinicaltrials.gov/ct2/show/NCT05633602?recrs=ab&lead=swog&draw=2&rank=10
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
https://classic.clinicaltrials.gov/ct2/show/NCT05633615?recrs=ab&lead=swog&draw=2&rank=9
Axicabtagene Ciloleucel -- Gilead
Lisocabtagene Maraleucel -- Bristol-Myers Squibb
Tisagenlecleucel -- Novartis
Polatuzumab Vedotin -- Roche
Mosunetuzumab -- Roche
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05642572?recrs=ab&lead=swog&draw=2&rank=8
Capmatinib -- Novartis
Osimertinib -- AstraZeneca
Ramucirumab -- Eli Lilly
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://classic.clinicaltrials.gov/ct2/show/NCT05806515?recrs=ab&lead=swog&draw=2&rank=6
Carboplatin -- Bristol-Myers Squibb
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05890352?recrs=ab&lead=swog&draw=2&rank=5
Lenalidomide -- Bristol-Myers Squibb
Tafasitamab -- Incyte
Tazemetostat -- Ipsen
Zanubrutinib -- BeiGene
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05929768?recrs=ab&lead=swog&draw=2&rank=4
Carboplatin -- Bristol-Myers Squibb
Paclitaxel -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=ab&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=ab&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04268550?recrs=bd&lead=swog&draw=2&rank=6
Selpercatinib -- Eli Lilly
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05096663?recrs=bd&lead=swog&draw=2&rank=4
Nogapendekin Alfa -- ImmunityBio
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=bd&lead=swog&draw=2&rank=1
Amivantamab -- Janssen and Genmab
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=bd&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA
Well that doesn’t answer the question at all that why haven’t they answered this question still . No patients are being enrolled , data has long been published and locked . Trial has officially ended . And above has been true for few years now . So I haven’t seen a single logical reason in your post to explain above .
It is two year old post . Data is already published ?
Not following you quite clearly. That meeting was dated back in 2022.
Just hoping to get approval in May so that it will bring spotlight in ASCO 2024.
Great find, hopefully we'll have the UK approval before the presentation.
I wonder if it's possible for the company to put the presentation on their website after the conference ends.
Gary
No, she started with a rare form of kidney cancer that normally is very deadly, but was thought cured after 10 years. She had some good years before it returned with a vengeance. I hoped that DCVax-Direct might be available in trials, but clearly it didn't happen. She did have surgery, then substantial chemo, but she refused additional surgery which might have given her more time, but couldn't possibly be curative.
I've recently had a few friends choose quality of life over duration when it came to treatment they'd accept. The beauty of our vaccine is that it offers both quality and duration, especially if the right other therapeutics are combined with it. I often think that drugmakers fail to emphasize the quality of life with their products when they're not found to extend life more than the SOC but in fact are easier to tolerate for the patient.
Gary
No, she started with a rare form of kidney cancer that normally is very deadly, but was thought cured after 10 years. She had some good years before it returned with a vengeance. I hoped that DCVax-Direct might be available in trials, but clearly it didn't happen. She did have surgery, then substantial chemo, but she refused additional surgery which might have given her more time, but couldn't possibly be curative.
I've recently had a few friends choose quality of life over duration when it came to treatment they'd accept. The beauty of our vaccine is that it offers both quality and duration, especially if the right other therapeutics are combined with it. I often think that drugmakers fail to emphasize the quality of life with their products when they're not found to extend life more than the SOC but in fact are easier to tolerate for the patient.
Gary
More longs who think the MMs admitted guilt in the MTD.
This is a laugh. Longs whop think that should be investing in AI as they clearly lack the native version.
BTW, your post about UK making DCVax a profit center is a hoot. May start a separate thread on that one.
Newman thx for your response… but as to: “Why no one is disputing Ex here, I don't understand.”? It’s because he spews nothing but anti-NWBO BULLSHIT.
Alias 18 years old w/nearly 18,000 posts!! Think about that! Profile says the alias is also interested in NVCR yet there’s just 1 post in the past YEAR on that board, but 20 on this board just THIS MONTH.
Prolific FUD…. IMHO😉
Hey Perk.
The whole "I said I was an IT guy" came from a post where I talked about understanding microprocessors and SOCs and how they were used in embedded systems as that is what I do for a living.
That you, Hoff, druggie and the rest are so f;'ing dumb to think this makes me an IT guy is comical.
Tool on.
It's funny to read his posts ....IT guys think they are engineers. I deal with them eveyday. Their job is to automate simple tasks using off the shelf products. We call them "the other guys" you know, the paperwork bitches :)
Inquirig,
Your “?!!!!” says it all. The question mark makes it a non declarative sentence so you are admitting to either not knowing your statement to be true or you know it’s not true and are protecting this statement as an opinion under the assumption of not knowing. Nice try but not good enough. Best wishes.
Ex lol you are a self processed IT guy ..
Stop pretending you are a lawyer
manibiotech,
Trial integrity was only one part of what I said. I believe that bad actors, apart from Mr. Neil Woodford, also came into non public information. I have no problem believing that folks with non disclosed information might have been approached by those with an agenda. Why do you think the company was attacked so heavily in 2015 when the attackers apparently went into plan B?
Mr. Woodford appeared to be somewhat acting separately at first with his own plans and not in concert with the hedge funds and market makers targeting NWBO. Hints of this came when Steven Giardino said he lost money on the 2015 April? options when Mr. Woodford had just purchased shares at a premium and share price was soaring. By October the rift was very obvious between Mr. Woodford and NWBO and cemented by different picks for the BOD by January 2016. The threats by Mr. Woodford to do his own investigation never materialized and instead he found himself relieved/dismissed from fiduciary duties at his funds.
I suspect that Mr. Woodford himself and his funds became a target and were pretty easily taken down because of the high risk ventures he was involved with that also had extremely low liquidity in some cases. Bottom line is that his dismissal led to the sell off of NWBO shares in his holdings that led to shares being sold as low as $.14 in 2017 because of the sizable holdings his funds had accumulated.
The lesson for all the bad actors is that when you mess with Linda Powers you are very likely to go down in flames. It may take a while and investors not understanding what has been going on and planning accordingly have been hurt during the process but in the long run investors expect to be richly rewarded while the perps will do their walk of shame for all to see. Best wishes.
Inquiring “ you have everything wrong quote. Brilliantly hilariously “ironic”
In fact “ ironic inquiring”… though I suspect that irony is beyond you…..
However, let’s go to “ you have everything wrong” . This from the guy/ gal/ bot who ..when skewered by my pointing out a few facts declared me to be someone who had only just appeared on the board… WHEN the simplest look at my profile shows that I have been here ( holding my shares and calling out idiot narratives) for nearly a decade.
Ironic Inquirig = rubbish ( and in spectacular volume). But try not to be harsh on him/ her / bot.
He made that up or is simply ignorant.
https://www.whitehouse.gov/cancermoonshot/
"In the meantime, Biden’s leaning on the agencies to keep moonshot programs going and pursuing private sector help that costs the government nothing. Last month, he said the country’s largest health insurers were expanding services to help patients and their families navigate health care treatments for cancer."
<<< You are just showing all the users here just how ignorant you are.
But I am here to help you. Here is a little info to help you brush up on your MHRA approval skills.>>> 🤡
Can you even read your own post? WTF is wrong with you.???? " After the MAA has been submitted". NOT after the MAA has been approved!
The company’s approved PIP includes two clinical trials: one for newly diagnosed pediatric high grade glioma (HGG), and one for recurrent pediatric HGG. In each of the trials, 24 patients will be treated with DCVax-L on the same treatment schedule as in the company’s phase III trial in adult glioblastoma patients.
The approval may include a deferral allowing the pediatric clinical trials to actually be carried out after the MAA has been submitted,
The company’s approved PIP includes a deferral under which the pediatric trials are anticipated****** to be undertaken after an MAA application has been submitted******.
Ok, it has been submitted, now the trials must begin?!!!!
Jeez, every weekend full of clueless replies to ex and his ilk, as if it does anything but feed the fire. So ignorantly stupid this behavior is...
What another load of crap from the head $hitter. If I remember correctly, they said that spoofing was the way things are done, and if they had to stop it would destroy the markets. I guess it doesn't matter to them that it is illegal. On top of that, the video of Griffin saying that they set the prices of securities and drive them there. What kind of a twisted individual could support someone with this mindset?
I think you need to brush up on your DD. NW only needs to PIP plan approved, not active ongoing or completed trials for submission and possible approval of DCVax in adults. Once again, you are just showing all the users here just how ignorant you are. Nothing you say should be taken seriously, not even a little.
But I am here to help you. Here is a little info to help you brush up on your MHRA approval skills.
https://www.labiotech.eu/trends-news/northwest-biotherapeutics-cancer-pip-approval/
You have everything wrong
It is a lie. I read in their documents that they admitted spoofing on behalf of their clients and that netted them like $64k gains; or something else like their clients spoofed but they didn't stop them. Why no one is disputing Ex here, I don't understand. Did I read it all wrong?
I wish you and your family well.
ilovetech Agreed and there in is the stuff that keeps me awake at night. Looking forward to a good nights sleep on Nov 6th.
So, now that NIH UK has told us to expect cancer vaccines in about five years the next question is how does NWBO intend to raise cash for the likely Plll / confirmatory trial? Also where's the next land purchase for her next CDMO?
Was your sister's BC triple negative?
That's what happened to my late wife.
voloda69 - The fact that most have no idea what
Im still not sure how they prove a monetary value on damages.. MMs will have their own expert witnesses to counter.
Flipper, it would seem to me that an mRNA vaccine that was intended to prevent the onset of cancer, or used on discovery of cancer prior to surgery could be beneficial, likewise once the cancer was detected DCVax-Direct could be effective prior to surgery. Once surgery occurs, I've got to believe that a vaccine that's made from that specific tumor would be more effective than an mRNA vaccine.
I'm certainly not an expert, but this would seem like common sense to me.
Frankly when my wife was determined to have breast cancer, over a quarter century ago, I was surprised at the time between discovery and surgery, it took months, and today it seems no different. I believe that treatment with DCVax-Direct could be initiated within weeks of discovery of an operable tumor, and should be injected into that tumor well before surgery. The greatest benefit of such treatment would hopefully get some anti-cancer action into the mets which left untreated can result in the cancer returning years, even decades later in multiple organs. If the mRNA vaccine could potentially do the same, perhaps both should be used.
If the mRNA vaccine is given as a preventative to cancers, like many other vaccines we all take, once a cancer occurs in a patient who's already had the vaccine, I don't know that more vaccine would have any effect whereas both DCVax-Direct and L post surgery should be effective. We know that by themselves they're not curative, but other therapeutics become more effective and lives are certainly being lengthened and at some point the cancer may be determined to be cured. I frankly don't know if all the longest living patients treated with DCVax-L are considered to be cured. It's been 10 years since I had stem cells for leukemia and I still return to City of Hope quarterly to determine I'm still in complete remission, I cannot consider myself cured as long as my Dr. still believes such testing is necessary.
I should note, my sister was thought cured by her oncologist until a body scan done by her new internist found tiny tumors in several places that ultimately proved fatal, it was roughly a decade after the initial cancer was treated. I don't believe the old sentiment that after 5 years cancer free your cured is currently considered the SOC for most cancers.
Gary
Agreed that the amended 10K and the new loan suggest that NWBO
has completed the intense work of responding to the MHRA and is
confident of MAA approval in the near future. While this suggests to
me that the MAA is now "cemented" I do believe that NWBO is presently
too busy to engage in combo trials with a BP but will do so after MAA
approval and certification of the EDEN methodology.
Big man wanted a cut but Linda told him “Ef-off I will go via UK and I won’t have to share with you you corrupted $cumbag.”
So RevImmune solely owned by LP would prefer to use other DC vaccines while LP knew very well about the efficacy of DCVax-L. Do you have other smart ways to counter my point?
Do you have any idea how many trials of DC vaccines have been run?
See this paper for a clue: The first 1000 dendritic cell vaccinees
That is old, I am sure many hundreds have been ran since then.
You are saying that they skipped any safety and dosage determination on the new DC vaccine and directly combined with CYT107. They did the same on the ATL-DC. No safety and dosage escalation evaluation and they adopted measures that were never tried before in any other trials. Are you kidding me?
No it's worse. Since the Gov't is broke, and funds, which in large part has always been laundered to off-ledger accouns has turned to taking a cut from human trafficking cartels who make $13 million a day.
Cartman from South Park comes to mind.
Dstock, besides Dr Bosch, Dr LL, another wonderful is Dr Mark Lowdell. I am glad actually this Dr is the partner of LP in that company you mentioned. He is an expert in Immunotherapy too. One day we will know the great results of the collaboration with him.
Followers
|
1619
|
Posters
|
|
Posts (Today)
|
110
|
Posts (Total)
|
689141
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |